Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial (Q35567212)
Jump to navigation
Jump to search
scientific article published on 13 May 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial |
scientific article published on 13 May 2014 |
Statements
1 reference
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial (English)
1 reference
Karim Fizazi
1 reference
Nadine Houede
1 reference
Eugene D Kwon
1 reference
Charles G Drake
1 reference
Howard I Scher
1 reference
Alberto Bossi
1 reference
Alfons J M van den Eertwegh
1 reference
Ricardo Santos
1 reference
Hakim Mahammedi
1 reference
Siobhan Ng
1 reference
Fabio A Franke
1 reference
Neeraj Agarwal
1 reference
Andries M Bergman
1 reference
Tudor E Ciuleanu
1 reference
Ernesto Korbenfeld
1 reference
Lisa Sengeløv
1 reference
Steinbjorn Hansen
1 reference
Christopher Logothetis
1 reference
Tomasz M Beer
1 reference
M Brent McHenry
1 reference
Paul Gagnier
1 reference
David Liu
1 reference
Winald R Gerritsen
1 reference
CA184-043 Investigators
1 reference
1 reference
Identifiers
1 reference